期刊
PARKINSONISM & RELATED DISORDERS
卷 98, 期 -, 页码 47-52出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2022.04.007
关键词
Parkinson's disease; Impaired bed mobility; Turning in bed; Prodromal Parkinson's disease; Motor complications
资金
- Michael J. Fox Foundation for Parkinson's Research
- Abbvie
- Acure
- Allergan
- Amathus
- Avid
- Biogen
- Bial Biotech
- Bio-legend
- Bristol-Myers Squibb
- Calico
- Celgene
- Covance
- Dacapo brain-science
- Jenali
- 4D Pharma plc
- GE Healthcare
- Edmond J. Safra phil-anthropic foundation
- Genentech
- GlaxoSmithKline
- Golub Capital
- Handl Therapeutics
- Insitro
- Janssen Neuroscience
- Lilly
- Lundbeck
- Merck
- Meso Scale Discovery
- Neurocine
- Pfizer
- Piramal
- Prevail
- Roche
- Sanofi Genzyme
- Servier
- Takeda
- Teva
- UCB
- Verily and Voyager therapeutics
This study suggests that impaired bed mobility can be a clinical symptom for screening prodromal PD and predicting motor complications in early PD.
Background: Wearable technology research suggests that nocturnal movements are disturbed in early Parkinson's disease (PD). In this study, we investigate if patients also already experience impaired bed mobility before PD diagnosis. Furthermore, we explore its association with motor and nonmotor features and its value for phenoconversion and disease progression prediction. Methods: PPMI data were downloaded for de novo PD subjects, subjects at-risk for developing a synucleinopathy (with isolated REM sleep behavior disorder, hyposmia or a pathogenic genetic variant) and controls. Impaired bed mobility was assessed with the MDS-UPDRS part 2 item 9. A frequency analysis was performed. Multivariable logistic regression analyses were used to investigate the association with other PD variables. Cox proportional-hazards models were used to test if difficulties with turning in bed could predict phenoconversion. Linear mixed models were used to evaluate if difficulties with turning in bed could predict disease progression. Results: Of the at-risk subjects, 9.2-12.5% experienced difficulties with turning in bed vs. 25.0% of de novo PD subjects and 2.5% of controls. Impaired turning ability was associated with MDS-UPDRS motorscore (axial signs in the at-risk group, bradykinesia in the de novo PD group) and SCOPA-AUT score (gastrointestinal symptoms). In addition, difficulties with turning in bed were a significant predictor for phenoconversion in the at-risk group and for development of motor complications in the de novo PD group. Conclusion: Our findings suggest that difficulties with turning in bed can be helpful as clinical symptom for a prodromal PD screening and for motor complication prediction in early PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据